[go: up one dir, main page]

AU2002224478A1 - Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke - Google Patents

Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke

Info

Publication number
AU2002224478A1
AU2002224478A1 AU2002224478A AU2447802A AU2002224478A1 AU 2002224478 A1 AU2002224478 A1 AU 2002224478A1 AU 2002224478 A AU2002224478 A AU 2002224478A AU 2447802 A AU2447802 A AU 2447802A AU 2002224478 A1 AU2002224478 A1 AU 2002224478A1
Authority
AU
Australia
Prior art keywords
aminoalkylpyridines
delta2
triazoline
anticonvulsants
stroke
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002224478A
Inventor
Pankaja K. Kadaba
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
K and K Biosciences Inc
Original Assignee
K and K Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by K and K Biosciences Inc filed Critical K and K Biosciences Inc
Publication of AU2002224478A1 publication Critical patent/AU2002224478A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4192—1,2,3-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/38—Radicals substituted by singly-bound nitrogen atoms having only hydrogen or hydrocarbon radicals attached to the substituent nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002224478A 2000-11-02 2001-11-02 Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke Abandoned AU2002224478A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US24493000P 2000-11-02 2000-11-02
US60244930 2000-11-02
US30736001P 2001-07-25 2001-07-25
US60307360 2001-07-25
PCT/US2001/042898 WO2002036119A1 (en) 2000-11-02 2001-11-02 Δ2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke

Publications (1)

Publication Number Publication Date
AU2002224478A1 true AU2002224478A1 (en) 2002-05-15

Family

ID=26936896

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002224478A Abandoned AU2002224478A1 (en) 2000-11-02 2001-11-02 Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke

Country Status (4)

Country Link
US (3) US6638954B2 (en)
EP (1) EP1343497A4 (en)
AU (1) AU2002224478A1 (en)
WO (1) WO2002036119A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662101B2 (en) * 2003-09-18 2010-02-16 Cardiac Pacemakers, Inc. Therapy control based on cardiopulmonary status
US7575553B2 (en) * 2003-09-18 2009-08-18 Cardiac Pacemakers, Inc. Methods and systems for assessing pulmonary disease
US20050142070A1 (en) * 2003-09-18 2005-06-30 Hartley Jesse W. Methods and systems for assessing pulmonary disease with drug therapy control
US7887493B2 (en) * 2003-09-18 2011-02-15 Cardiac Pacemakers, Inc. Implantable device employing movement sensing for detecting sleep-related disorders
US7610094B2 (en) * 2003-09-18 2009-10-27 Cardiac Pacemakers, Inc. Synergistic use of medical devices for detecting medical disorders
US8002553B2 (en) * 2003-08-18 2011-08-23 Cardiac Pacemakers, Inc. Sleep quality data collection and evaluation
US7591265B2 (en) 2003-09-18 2009-09-22 Cardiac Pacemakers, Inc. Coordinated use of respiratory and cardiac therapies for sleep disordered breathing
US8030332B2 (en) * 2006-02-01 2011-10-04 Merck Sharp & Dohme Corp. Potassium channel inhibitors
EP1921071A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,3- triazole derivatives as sigma receptor inhibitors
EP1921073A1 (en) * 2006-11-10 2008-05-14 Laboratorios del Dr. Esteve S.A. 1,2,4-Triazole derivatives as sigma receptor inhibitors
EP2752411A1 (en) * 2013-01-07 2014-07-09 Laboratorios Del Dr. Esteve, S.A. 1,2,3-triazole-4-amine derivatives for the treatment of sigma receptor related diseases and disorders
WO2023154794A1 (en) * 2022-02-09 2023-08-17 University Of North Texas Health Science Center Drug repurposing for delayed treatment of ischemic stroke

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2797224A (en) * 1955-01-24 1957-06-25 Schenley Ind Inc Process for preparing picolyl secondary amines
US3654290A (en) * 1970-03-27 1972-04-04 Hoffmann La Roche Intermediates for 5-(pyridylalkyl) pyridoindole derivatives
US4511572A (en) 1983-03-18 1985-04-16 The University Of Kentucky Research Foundation Triazoline anticonvulsant drugs
US4689334A (en) 1983-03-18 1987-08-25 The University Of Kentucky Research Foundation Triazoline anticonvulsant compounds and compositions
US4618681A (en) 1983-03-18 1986-10-21 The University Of Kentucky Research Foundation Aryl substituted 1H-4,5-dihydro-1,2,3-triazoles as anticonvulsants
US4610994A (en) * 1984-04-26 1986-09-09 The University Of Kentucky Research Foundation 1,2,3-triazole anticonvulsant drugs
US4874775A (en) * 1985-06-11 1989-10-17 Eli Lilly And Company Agriculturally useful sulfonamides
US4820721A (en) 1988-04-11 1989-04-11 Kadaba Pankaja K 1-aryl-5-(2-oxo-1-pyrrolidinyl)-1,2,3-triazolines as novel anticonvulsants
US5648369A (en) * 1991-11-20 1997-07-15 University Of Kentucky Research Foundation Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists
US5942527A (en) * 1997-08-27 1999-08-24 K & K Biosciences, Inc. Hydrazones, hydrazines, semicarbazones and thiosemicarbazones derived from pyridyl ketones as anticonvulsant drugs and excitatory amino acid antagonists
US6083964A (en) * 1998-02-18 2000-07-04 K And K Biosciences, Inc. Optical resolution of racemic aminoalkylpyridine anticonvulsants and (+) aminoalkylpyridine enantiomers as highly potent orally effective anticonvulsant drugs and excitatory amino acid antagonists
US6514687B1 (en) * 1998-12-14 2003-02-04 Vertex Pharmaceuticals (San Diego), Llc Optical molecular sensors for cytochrome P450 activity

Also Published As

Publication number Publication date
WO2002036119A1 (en) 2002-05-10
EP1343497A4 (en) 2005-01-26
US20040073039A1 (en) 2004-04-15
US20060058357A1 (en) 2006-03-16
EP1343497A1 (en) 2003-09-17
US20020111371A1 (en) 2002-08-15
US6638954B2 (en) 2003-10-28

Similar Documents

Publication Publication Date Title
PT1478339E (en) Pharmaceutical formulations of antineoplastic agents, in particular temozolomide, processes of making and using the same
PL370501A1 (en) Cyclosporine analogue mixtures and their use as immunomodulating agents
AU2002224478A1 (en) Delta2,-1,2,3-triazoline anticonvulsants and their active metabolite analogues, the aminoalkylpyridines, are excitatory amino acid antagonists and antiischemic agents, useful in the treatment of cerebral ischemia resulting from stroke
HUP0303825A3 (en) 1h-benzimidazole and 3h-imidazo-[4,5b]pyridine-derivatives, their use and pharmaceutical compositions containing them
IL168102A0 (en) Chk-, pdk-and akt-inhibitory pyrimidines, their production and use as pharmaceutical agents
IS3023B (en) 3 - ((3R, 4R) -4-methyl-3- [methyl- (7H-pyrrolo [2,3-d] pyrimidin-4-yl) -amino] -piperidinyl) -3-oxo-propionitrile as a protein kinase inhibitor
HUP0400732A3 (en) Pharmaceutically active uridine esters
AU2002245216A1 (en) Imaged nonwoven fabric for imparting an improved aesthetic texture to surfaces
HUP0402113A3 (en) 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity, preparation and use thereof
ZA200501082B (en) Substituted 1,3-diphenylprop-2-en-1-one derivatives and preparation and uses thereof
HUP0004310A3 (en) Cyclic amino acids, and derivatives thereof and pharmaceutical compositions comprising the said compounds as active agents
EE200300370A (en) Acylated 6,7,8,9-tetrahydro-5H-benzocycloheptenylamines, process for their preparation, use and pharmaceutical preparation
AU2002361811A8 (en) 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
EP1178786A4 (en) Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
DE60131760D1 (en) DEVICE FOR THE ADMINISTRATION OF PHYSIOLOGICALLY ACTIVE ACTIVE IN POWDER FORM
AU2001268422A1 (en) Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders
PL375603A1 (en) Depot formulations of arylheterocyclic active agents in the form of a suspension
IL160190A0 (en) Use of copolymer to produce a galenic form containining a peptide or a protein as active agent
HUP0202842A3 (en) Spherical telithromycin clusters, method for their production and use thereof in the pharmaceutical compositions
HUP0003357A3 (en) Cyclic azapeptides with angiogenic effect, pharmaceutical compositions comprising them, processes for producing thereof and their use
PT1358159E (en) TARTRATO AND PHOSPHATE 3.4 DIAMINOPYRIDINE, THEIR PHARMACEUTICAL COMPOSITIONS AND THEIR USES
IL164901A0 (en) Optically active beta-aminoketones, optically active 1,3-aminoalcohols and processes for preparing them
FR2826366B1 (en) PREPARATION OF MASK ISOCYANATES, IN PARTICULAR MASK POLYISOCYANATES
AU2002310922A1 (en) Interferons in the treatment of ischemia
ZA200410062B (en) Novel adenosine analogues and their use as pharmaceutical agents